MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS

(19)

(11)

EP 3 474 885 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.06.2023 Bulletin 2023/25

(45)	Mention of the grant of the patent:
	10.05.2023 Bulletin 2023/19

(21)	Application number: 17821125.6

(22)	Date of filing: 28.06.2017

(51)

International Patent Classification (IPC):

A61K 9/00^(2006.01)
A61K 9/50^(2006.01)
A61P 1/00^(2006.01)
A61P 1/12^(2006.01)
A61P 31/04^(2006.01)
A61P 39/02^(2006.01)
A61K 31/424^(2006.01)
A61K 38/50^(2006.01)

A61K 9/48^(2006.01)
A61K 47/32^(2006.01)
A61P 1/04^(2006.01)
A61P 29/00^(2006.01)
A61P 39/00^(2006.01)
A61P 43/00^(2006.01)
A61K 45/06^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 38/50; A61K 9/0053; A61K 47/32; A61K 9/4891; A61K 9/5026; A61K 9/5078; C12Y 305/02006; A61K 45/06; A61K 31/424; A61P 1/00; A61P 1/04; A61P 1/12; A61P 29/00; A61P 31/04; A61P 39/00; A61P 39/02; A61P 43/00

	C-Sets:
	A61K 31/424, A61K 2300/00;

(86)	International application number:
	PCT/US2017/039672

(87)	International publication number:
	WO 2018/005606 (04.01.2018 Gazette 2018/01)

(54)	MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS SCHUTZ DER DARMFLORA VOR ORALEN ANTIBIOTIKA PROTECTION DU MICROBIOME CONTRE LES ANTIBIOTIQUES ORAUX

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

28.06.2016 US 201662355599 P

(43)	Date of publication of application:
	01.05.2019 Bulletin 2019/18

(73)	Proprietor: Theriva Biologics, Inc.
	Rockville, MD 20850 (US)

(72)	Inventors:
	KALEKO, Michael Rockville, MD 20850 (US) CONNELLY, Sheila Rockville, MD 20850 (US)

(74)	Representative: Boxall, Sarah Jane
	Boxall IPM Ltd 9 King Street Sandwich Kent CT13 9BT Sandwich Kent CT13 9BT (GB)

(56)

References cited: :

WO-A1-2008/065247
WO-A1-2016/057744
WO-A2-2015/161243

WO-A1-2011/148041
WO-A1-2016/137993
US-B2- 8 273 376

KALEKO, M ET AL.: 'Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection' ANAEROBE vol. 41, 02 June 2016, pages 58 - 67, XP055444836

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).